Skip to main content
. Author manuscript; available in PMC: 2022 Jul 5.
Published in final edited form as: Eur J Med Chem. 2021 Apr 4;219:113425. doi: 10.1016/j.ejmech.2021.113425

Figure 5.

Figure 5.

Mechanistic study of MDM2-p53 degradation induced by CC-885. (A) Immunoblot of MDM2, p53 and GSPT1 following incubation with CC-885 at indicated concentration for 4 h; (B) MDM2 and p53 degradation induced by CC-885 is dependent on CRBN and the proteasome. Cells were pre-treated with proteasome inhibitor MG132 (5 μM), MLN4924 (3 μM), CRBN ligand lenalidomide (20 μM) and MDM2 inhibitor AMG232 (2 μM) for 1 h, followed by treatment with DMSO or CC-885 for 4 h; (C) Study of the ternary complex formation between CRBN/DDB1-MDM2 by time-resolved fluorescence energy transfer (TR-FRET).